Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2 / COVID-19 pandemic

References

• Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, thrusting corona viruses into the spotlight. Viruses. 2019;11:59.
   PubMed Web of Science ®Google Scholar
• Contini C, Di Nuzzo M, Barp N, Bonazza A, De Giorgio R, Tognon M, Rubino S. The novel zoonotic COVID-19 pandemic: an expected global health concern. J Infect Dev Ctries. 2020;14:254–64.
   PubMed Web of Science ®Google Scholar
• Kelvin DJ, Rubino S. Fear of the novel coronavirus. J Infect Dev Ctries. 2020;14:1–2.
   PubMed Web of Science ®Google Scholar
• Lau SKP, Luk HKH, Wong ACP, Li KSM, Zhu L, He Z, Fung J, Chan TTY, Fung KSC, Woo PCY. Possible bat origin of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26:1542.
   PubMed Web of Science ®Google Scholar
• Singhal T. A review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87:281–86.
   PubMed Web of Science ®Google Scholar
• Shanmugaraj B, Malla A, Phoolcharoen W. Emergence of novel Coronavirus 2019-nCoV: need for rapid vaccine and biologics development. Pathogens. 2020;9:148.
   PubMed Web of Science ®Google Scholar
• Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38:10–18.
   PubMed Web of Science ®Google Scholar
• Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30:313–24.
   PubMed Web of Science ®Google Scholar
• Amin Jafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. 2020;83:106455.
   PubMed Web of Science ®Google Scholar
• Cevik M, Bamford C, Ho A. COVID-19 pandemic – A focused review for clinicians. Clin Microbiol Infect. 2020. doi:https://doi.org/10.1016/j.cmi.2020.04.023.
   Google Scholar
• de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ Host factors in coronavirus replication. Current Topics in Microbiology and Immunology. 2018; 419:1–42
   PubMed Web of Science ®Google Scholar
• Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55:10591.
   Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–73.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, Chen YM, Wang W, Hu Y, Song ZG, Tao ZW, Tian JH, Pei YY, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. BioRxiv. 2020. doi:https://doi.org/10.1101/2020.01.24.919183
   Google Scholar
• Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:372.
   PubMed Web of Science ®Google Scholar
• Hu D, Zhu C, Ai L, He T, Wang Y, Ye F, Yang L, Ding C, Zhu X, Lv R, et al. Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats. Emerg Microbes Infect. 2018;7:1–10.
   PubMed Web of Science ®Google Scholar
• Liu P, Chen W, Chen J-P. Viral metagenomics revealed sendai virus and Coronavirus infection of Malayan Pangolins (Manis javanica). Viruses. 2019;11:979.
   PubMed Web of Science ®Google Scholar
• Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC, Tong YG, Shi YX, Ni XB, Liao YS, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 2020;583:282–85.
   PubMed Web of Science ®Google Scholar
• Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. Science. 2020;368:1016–20.
   PubMed Web of Science ®Google Scholar
• Kim YI, Kim SG, Kim SM, Kim EH, Park SJ, Yu KM, Chang JH, Kim EJ, Lee S, Casel MAB, et al. Infection and rapid transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe. 2020;27:704–09.
   PubMed Web of Science ®Google Scholar
• Gollakner R, Capua I. Is COVID-19 the first pandemic that evolves into a panzootic? Vet Ital. 2020;56:11–12.
   Web of Science ®Google Scholar
• Gui M, Song W, Zhou H, Xu J, Chen S, Xiang Y, Wang X. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 2017;27:119–29.
   PubMed Web of Science ®Google Scholar
• Paules CI, Marston HD, Fauci AS. Coronavirus infections - more than just the common cold. JAMA. 2020;323:707.
   PubMed Web of Science ®Google Scholar
• Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–66.
   PubMed Web of Science ®Google Scholar
• Deng J, Jin Y, Liu Y, Sun J, Hao L, Bai J, Huang T, Lin D, Jin Y, Tian K. Serological survey of SARS‐CoV‐2 for experimental, domestic, companion and wild animals excludes intermediate hosts of 35 different species of animals. Transbound Emerg Dis. 2020;00:1–5.
   Google Scholar
• Molenaar RJ, Vreman S, Hakze-van der Honing RW, Zwart R, de Rond J, Weesendorp E, Smit LA, Koopmans M, Bouwstra R, Stegeman A, et al. Clinical and pathological findings in SARS-CoV-2 disease outbreaks in farmed mink (Neovison vison). Vet Pathol. 2020;300985820943535. doi:https://doi.org/10.1177/0300985820943535.
   Google Scholar
• Oreshkova N, Molenaar RJ, Vreman S, Harders F, Munnink BB, Hakze-van der Honing RW, Gerhards N, Tolsma P, Bouwstra R, Sikkema RS, et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Eurosurveillance. 2020;25:2001005.
   Web of Science ®Google Scholar
• OIE. Letter to OIE about the COVID-19 situation in Denmark;2020 July 3 [accessed 2020 July 18]. https://www.oie.int/fileadmin/Home/MM/Update_1_Letter_to_OIE_about_the_COVID-19_situation_in_Denmark.pdf
   Google Scholar
• Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, et al. A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:e1−e9.
   Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–69.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Graham R, Baric RS, Li F. receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. J Virol. 2020;94:e00127−20.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wu Q, Zhang Z. Pangolin homology associated with 2019-nCoV. bioRxiv. 2020. doi:https://doi.org/10.1101/2020.02.19.950253.
   Google Scholar
• Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, Sun J, Chang C. The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
   PubMed Web of Science ®Google Scholar
• Kluytmans-van den Bergh M, Buiting A, Pas S, Bentvelsen R, Bijllaardt W, van Den, Oudheusden AV, Rijen MV, Verweij J, Koopmans M, Kluytmans J. SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020. medRxiv. 2020. 10.1101/2020.03.23.20041913.
   Google Scholar
• Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z, Zhang Q, Qi W. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut. 2020;69:1141–43.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, Akdis CA, Gao Y. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75:1730–41.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. J Med Virol. 2020;92:568–76.
   PubMed Web of Science ®Google Scholar
• Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41:1858.
   PubMed Web of Science ®Google Scholar
• Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, et al. Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–90.
   PubMed Web of Science ®Google Scholar
• Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory Coronavirus 2 infection: a cross-sectional study. Clin Infect Dis. 2020;71:889–90.
   PubMed Web of Science ®Google Scholar
• Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:212–13.
   PubMed Web of Science ®Google Scholar
• Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, Wu K. Characteristics of ocular findings of patients with Coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138:575.
   PubMed Web of Science ®Google Scholar
• General Office of National Health Commission; General Office of National Administration of Traditional Chinese Medicine. Diagnostic and treatment protocol for Novel Coronavirus Pneumonia; (Trial version 6); 2020. [accessed 2020 February 20]. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml
   Google Scholar
• Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Behrens P, Böddinghaus B, Götsch U, Naujoks F, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med. 2020;382:1278–80.
   PubMed Web of Science ®Google Scholar
• Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus–infected pneumonia. N Engl J Med. 2020;382:1199–207.
   PubMed Web of Science ®Google Scholar
• Sun J, He W-T, Wang L, Lai A, Ji X, Zhai X, Li G, Suchard MA, Tian J, Zhou J, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020;26:483–95.
   PubMed Web of Science ®Google Scholar
• Ji W, Wang W, Zhao X, Zai J, Li X. Cross‐species transmission of the newly identified coronavirus 2019‐nCoV. J Med Virol. 2020;92:433–40.
   PubMed Web of Science ®Google Scholar
• Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207.
   PubMed Web of Science ®Google Scholar
• Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382:970–71.
   PubMed Web of Science ®Google Scholar
• Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177–79.
   PubMed Web of Science ®Google Scholar
• Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104:246–51.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Situation reports; [accessed 2020 April 22]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
   Google Scholar
• Yang Y, Shang W, Rao X. Facing the COVID‐19 outbreak: what should we know and what could we do? J Med Virol. 2020;92:536–37.
   PubMed Web of Science ®Google Scholar
• Medicine, G.O.o.N.H.C.O.o.S.A.o.T.C., The diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (Trial Version 6). 2020: p. 1–5.
   Google Scholar
• Li X, Zai J, Wang X, Li Y. Potential of large “first generation” human‐to‐human transmission of 2019‐nCoV. J Med Virol. 2020;92:448–54.
   PubMed Web of Science ®Google Scholar
• Wax RS, Christian MD. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anesth Can D’anesthésie. 2020;67:568–76.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–43.
   PubMed Web of Science ®Google Scholar
• Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14:125–28.
   PubMed Web of Science ®Google Scholar
• Bao L, Deng W, Huang B, Gao H, Ren L, Wei Q, Yu P, Xu Y, Liu J, Qi F, et al. The pathogenicity of 2019 Novel Coronavirus in hACE2 transgenic mice. bioRxiv. 2020. doi:https://doi.org/10.1101/2020.02.07.939389.
   Google Scholar
• Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, Chen X, Liu YX, Gao H, Jia YP, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12:1107–13.
   PubMed Web of Science ®Google Scholar
• Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26:6338–43.
   PubMed Web of Science ®Google Scholar
• Ter Meulen J, van den Brink EN, Poon LLM, Marissen WE, Leung CSW, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, et al. Human monoclonal antibody combination against SARS Coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3:e237.
   PubMed Web of Science ®Google Scholar
• Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9:382–85.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–24.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–63. doi:https://doi.org/10.1126/science.abb2507.
   PubMed Web of Science ®Google Scholar
• Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020;17:621–30.
   PubMed Web of Science ®Google Scholar
• Anon. Clover biopharmaceuticals vaccines programs. [accessed 2020 April 28]. http://www.cloverbiopharma.com/index.php?m=content&c=index&a=lists&catid=42.
   Google Scholar
• Significant step in COVID-19 vaccine quest. University of Queensland; 2020. [accessed 2020 April 28] https://www.uq.edu.au/news/article/2020/02/significant-step%E2%80%99-covid-19-vaccine-quest.
   Google Scholar
• Kim YC, Dema B, Reyes-Sandoval A. COVID-19 vaccines: breaking record times to first-in-human trials. NPJ Vaccines. 2020;5:1–3. doi:https://doi.org/10.1038/s41541-020-0188-3.
   PubMed Web of Science ®Google Scholar
• Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800; [accessed 2020 Mar 3]. http://ir.inovio.com/news-andmedia/news/press-release-details/2020/Inovio-Accelerates-Timeline-for-COVID-19-DNA-Vaccine-INO-4800/default.aspx.
   Google Scholar
• INO-4800 DNA Coronavirus Vaccine; 2020 [accessed 2020 May 18]. https://www.precisionvaccinations.com/vaccines/ino-4800-dna-coronavirus-vaccine.
   Google Scholar
• Moderna’s pipeline; [accessed 2020 April 28] https://www.modernatx.com/pipeline.
   Google Scholar
• mRNA platform: enabling drug discovery & development; [accessed 2020 April 28] https://www.modernatx.com/mrna-technology/mrna-platform-enabling-drug-discovery-development.
   Google Scholar
• hyFc platform; [accessed 2020 April 28]. http://www.genexine.com/m21.php.
   Google Scholar
• Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52:583‐589.
   PubMed Web of Science ®Google Scholar
• COVID-19 vaccine development; 2020; [accessed 2020 May 18]. https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development
   Google Scholar
• CanSino Bio enrols for Ph 2 trial of COVID-19 vaccine; [accessed 2020 May 18] https://www.biospectrumasia.com/news/37/15850/cansino-bio-enrols-for-ph-2-trial-of-covid-19-vaccine.html
   Google Scholar
• Cohen J. Vaccine designers take first shots at COVID-19. Science. 2020;368:14–16. doi:https://doi.org/10.1126/science.368.6486.14.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Draft landscape of COVID-19 candidate vaccines; 2020 July 15 [accessed 2020 July 18]. www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-e72692323504f4ce8bb2fe20709e830bd.pdf?sfvrsn=4c9a242c_5&download=true.
   Google Scholar
• Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92:479–90.
   PubMed Web of Science ®Google Scholar
• Baruah V, Bose S. Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV. J Med Virol. 2020;92:495–500.
   PubMed Web of Science ®Google Scholar
• Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research. 2020;9:72.
   PubMedGoogle Scholar
• Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent advances in the vaccine development against middle east respiratory syndrome-Coronavirus. Front Microbiol. 2019;10:1781.
   PubMed Web of Science ®Google Scholar
• Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12:254.
   PubMed Web of Science ®Google Scholar
• Clover Biopharmaceuticals vaccines programs. Anon 2020; [accessed 2020 April 28] http://www.cloverbiopharma.com/index.php?m
   Google Scholar
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19:149–50.
   PubMed Web of Science ®Google Scholar
• Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424–32.
   PubMed Web of Science ®Google Scholar
• Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007;25:1421–34.
   PubMed Web of Science ®Google Scholar
• Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M, Marasco WA. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol. 2005;79:5900–06.
   PubMed Web of Science ®Google Scholar
• Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JKC, Fooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013;31:1553–59.
   PubMed Web of Science ®Google Scholar
• Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PKS, Peng MY, Wan HL, Chen JH, Hu BS, Perng CL, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56:919–22.
   PubMed Web of Science ®Google Scholar
• Chan KH, Chan JFW, Tse H, Chen H, Lau CCY, Cai JP, Tsang AKL, Xiao X, To KKW, Lau SKP, et al. Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect. 2013;67:130–40.
   PubMed Web of Science ®Google Scholar
• Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Al-Hameed FM, Taha Y, Shindo N, Whitehead J, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4:709.
   PubMed Web of Science ®Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–54.
   PubMed Web of Science ®Google Scholar
• Hiatt A, Whaley KJ, Zeitlin L. Plant-Derived monoclonal antibodies for prevention and treatment of infectious disease. Microbiol Spectr. 2014;2:AID-0004-2012.
   PubMedGoogle Scholar
• Sainsbury F. Innovation in plant-based transient protein expression for infectious disease prevention and preparedness. Curr Opin Biotechnol. 2020;61:110–15.
   PubMed Web of Science ®Google Scholar
• Klasse PJ. Neutralization of virus infectivity by antibodies: old problems in new perspectives. Adv Biol. 2014;2014:1–24.
   Google Scholar
• Coughlin MM, Prabhakar BS. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol. 2012;22:2–17.
   PubMed Web of Science ®Google Scholar
• Li C, Xu X. Host immune responses to SARS Coronavirus in humans. In: S. K. Lal, editor.Molecular biology of the SARS-Coronavirus. Heidelberg, Germany: Springer; 2010. p. 259–78.
   Google Scholar
• Tseng CTK, Perrone LA, Zhu H, Makino S, Peters CJ. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol. 2005;174:7977–85.
   PubMed Web of Science ®Google Scholar
• Thiel V, Weber F. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev. 2008;19:121–32.
   PubMed Web of Science ®Google Scholar
• Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 Immunopathology and immunotherapy. Bioinformation. 2020;16:219–22.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, Deng Y, Wei S. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:203–08.
   PubMedGoogle Scholar
• Oh HL J, Ken-En Gan S, Bertoletti A, Tan YJ. Understanding the T cell immune response in SARS coronavirus infection. Emerg Microbes Infect. 2012;1:1–6.
   Web of Science ®Google Scholar
• Jodele S, Köhl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol. 2020. doi:https://doi.org/10.1111/bph.15187.
   Google Scholar
• Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, Grazzini G. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14:152‐157.
   Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46.
   PubMed Web of Science ®Google Scholar
• Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ. Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676‐78.
   Web of Science ®Google Scholar
• Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon III GM, Friedman-Moraco RJ, et al. the use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the united states. Clin Infect Dis. 2015;61:496–502.
   PubMed Web of Science ®Google Scholar
• Elshabrawy HA, Coughlin MM, Baker SC, Prabhakar BS. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One. 2012;7:e50366.
   PubMed Web of Science ®Google Scholar
• Davey RT Jr., Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375: 1448–56.
   PubMed Web of Science ®Google Scholar
• Hegarty PK, Sfakianos JP, Giannarini G, DiNardo AR, Kamat AM. COVID-19 and Bacillus Calmette-Guérin: what is the Link? Eur Urol Oncol. 2020;3:259–61.
   PubMed Web of Science ®Google Scholar
• Daza J, Charap A, Wiklund PN, Sfakianos JP. Role of the innate immune system in the development, progression, and therapeutic response of bladder cancer. Eur Urol Focus. 2020;6:650–52.
   PubMedGoogle Scholar
• Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van Crevel R, Rimmelzwaan GF, Pickkers P, Netea MG. BCG Vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J Infect Dis. 2015;212:1930–38.
   PubMed Web of Science ®Google Scholar